As of 06 Nov 2026 11:19 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from NatPSA/2023/008/DHSC (03 Jan 2024): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Byetta® (exenatide) 5micrograms/0.02ml and 10micrograms/0.04ml solution for injection 1.2ml pre-filled pensaffected product · inferred from phrasing | Discontinued, as stated | — not stated for this line | notice of 03 Jan 2024 |
| Saxenda® (liraglutide) and Wegovy® (semaglutide)named by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 03 Jan 2024 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Saxenda® (liraglutide) and Wegovy® (semaglutide) — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Glp-1 Receptor Agonists
Grouping under review The name on this page has not been matched to one BNF chemical with enough confidence to assert it; nothing here is grouped until a reviewer confirms it.
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name, confidence not asserted — grouping under review where marked
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 3 times on record since 2023. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 03 Jan 2024 | National Patient Safety Alert DHSC: Shortage of GLP-1 receptor agonists (GLP-1 RA) Update | Safety alert | — | NatPSA/2023/008/DHSC |
| 18 Jul 2023 | National Patient Safety Alert DHSC: Shortage of GLP-1 receptor agonists | Safety alert | — | NatPSA/2024/001/DHSC |
| 27 Jun 2023 | Medicine Supply Notification: GLP-1 receptor agonists* used in the management of type 2 diabetes | Supply notification | Tier 3 | MSN/2023/061 |
Also recorded under
Bracketed names seen in this medicine's notice titles: glp-1 ra. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2023)12 GLP-1 receptor agonists used in the management of type 2 diabetes · issued 12 Jul 2023 · valid until mid-2024, as stated · matched by name PDF ↗